Clinical Trials Directory

Trials / Completed

CompletedNCT03803176

Tissue Plasminogen Activator & Plasminogen Activator Inhibitor Type-1 In Gingival Tissues Of Chronic Periodontitis

Effect Of Periodontal Surgery On Tissue Plasminogen Activator And Plasminogen Activator Inhibitor Type-1 Gene Expression In Gingival Tissues Of Chronic Periodontitis Patients

Status
Completed
Phase
Study type
Observational
Enrollment
30 (actual)
Sponsor
Cairo University · Academic / Other
Sex
All
Age
30 Years – 50 Years
Healthy volunteers
Accepted

Summary

Tissue Plasminogen Activator and Plasminogen Activator Inhibitor Type-1 Gene Expression will be evaluated clinically and histopathologically through Hematoxylin and eosin as well as by quantitative reverse transcription polymerase chain reaction in the gingival tissues of chronic periodontitis in an attempt to investigate whether the expression of these proteins could be involved in the disease pathogenesis or not, and to assess as well if their expression will be affected by the applied surgical periodontal treatment.

Detailed description

30 subjects were enrolled in this study and divided into: Group I (Control Group): 10 periodontally healthy volunteers, Group II (Chronic Periodontitis Group): 20 patients suffering severe CP and Group III (Treated Group): 20 patients who were scheduled for OFD. Gingival samples were collected from all subjects at baseline and at 3 months after OFD from the CP patients. Then, Hematoxylin and eosin (H\&E) stained slides were examined and gene expression levels of t-PA and PAI-1 were measured in the gingiva through quantitative reverse transcription polymerase chain reaction (RT-PCR).

Conditions

Interventions

TypeNameDescription
PROCEDUREOpen Flap DebridementFull thickness flaps are elevated to fully expose the periodontaldefects. Defects are then fully debrided and the roots are carefully planned. Flaps are repositioned and sutured to obtain primary closure of the interdental space. This will be done for chronic periodontitis patients

Timeline

Start date
2018-02-12
Primary completion
2018-06-11
Completion
2018-08-14
First posted
2019-01-14
Last updated
2019-01-14

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT03803176. Inclusion in this directory is not an endorsement.